Stifel raised the firm’s price target on AtriCure (ATRC) to $48 from $36 and keeps a Buy rating on the shares. For 2025, AtriCure reiterated their January 13 initial revenue guidance of $517M-$527M, which brackets the firm’s prior sales projection so Stifel’s outlook “remains little-changed,” the analyst tells investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRC: